Repare Therapeutics Inc (RPTX) NPV

Sell:$1.43Buy:$1.47$0.03 (2.11%)

NASDAQ:0.11%
Prices delayed by at least 15 minutes
Sell:$1.43
Buy:$1.47
Change:$0.03 (2.11%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.43
Buy:$1.47
Change:$0.03 (2.11%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Key people

Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
Michael Zinda
Executive Vice President, Chief Scientific Officer
Sandra Alves
Senior Vice President, Chief Accounting Officer
Thomas Civik
Independent Chairman of the Board
David P. Bonita
Independent Director
Samarth Kulkarni
Independent Director
Susan M. Molineaux
Independent Director
Ann D. Rhoads
Independent Director
Click to see more

Key facts

  • EPIC
    RPTX
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7602731025
  • Market cap
    $61.76m
  • Employees
    129
  • Shares in issue
    42.89m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.